Almirall Prodesfarma, S.A.

25 articles with Almirall Prodesfarma, S.A.

• Almirall’s Nine-month 2022 Results

  11/10/2022

  Almirall, S.A., the global biopharmaceutical company based in Barcelona, has announced its 9M 2022 financial results.

• Simcere and Almirall Enter into a Licensing Agreement for IL-2 mu-Fc

  9/29/2022

  Simcere Pharmaceutical Group, an innovation and R&D-driven pharmaceutical company, and Almirall S.A., a global biopharmaceutical company focused on skin health; announced that they have entered into an exclusive licensing agreement for Simcere's IL-2 mutant fusion protein autoimmune drug candidate, SIM0278.

• Almirall and Simcere enter into a licensing agreement for IL-2-mu-Fc

  9/29/2022

  Almirall S.A. and Simcere Pharmaceutical Grou announced that they have entered into an exclusive licensing agreement for Simcere’s IL-2 mutant fusion protein autoimmune drug candidate, SIM0278.

• Evotec and Almirall Enter into a Multi-Target Alliance in Medical Dermatology

  5/19/2022

  Evotec SE and Almirall S.A., a global biopharmaceutical company focused on skin health, announced a multi-target alliance in Medical Dermatology.

• Almirall delivers good business performance in Q1 and reiterates full year 2022 guidance

  5/9/2022

  Almirall, S.A., the global biopharmaceutical company based in Barcelona, has announced its Q1 2022 financial results.

• Almirall's Full-Year 2021 Results : Almirall delivers high end of the 2021 upgraded guidance with solid performance from growth drivers

  2/21/2022

  Almirall, S.A. (ALM) a global biopharmaceutical company based in Barcelona, has announced its full-year 2021 financial results.

• Dr. Jorge Gallardo Ballart announces his intention to retire from his positions of President of the Board of Directors and Board member of Almirall

  2/21/2022

  Dr. Jorge Gallardo Ballart has announced in the Board of Directors' session on Friday 18th February, his intention to retire from his positions of Chairman of the Board of Directors and Board member with effect as of the end of the General Shareholders Meeting of Almirall, S.A. that will take place next 6 May 2022.

• Almirall delivers robust H1 performance and increases full-year guidance

  7/26/2021

  Almirall, S.A., the global biopharmaceutical company based in Barcelona, has announced its H1 2021 financial results.

• Almirall's solid core business Q1 performance boosted by Growth drivers momentum

  5/10/2021

  Good business performance with significant growth in Core EBITDA: Core Net Sales €215.4 MM (+5% year-on-year) and Core EBITDA €68.0MM (+46% year-on-year)

• Almirall's 2020 Full-Year Results

  2/22/2021

  Almirall appointed Gianfranco Nazzi as the new CEO, effective May 1, 2021. Mr. Nazzi will bring continuity to the strategy as the business prepares for important launches to support future growth prospects

• Almirall and MC2 Therapeutics enter a License, Collaboration and Commercialization Agreement for European Rights to Wynzora® Cream for treatment of Plaque Psoriasis

  2/17/2021

  Almirall S.A., a global biopharmaceutical company and MC2 Therapeutics, a commercial stage pharmaceutical company developing a new standard within topical therapies for autoimmune and chronic inflammatory conditions, announced an agreement under which MC2 Therapeutics has granted Almirall exclusive European rights to commercialize Wynzora® Cream for treatment of plaque psoriasis.

• Almirall announces collaborations with the University of South Australia and Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

  11/24/2020

  AlmirallShare, the open innovation platform of Almirall, S.A., announces two new collaborations with the University of South Australia and the Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau to find new pathways for the treatment of skin cancer and atopic dermatitis.

• Pablo Alvarez appointed to President and GM of Almirall US

  11/11/2020

  Almirall, S.A. the global biopharmaceutical company based in Barcelona, has announced that Pablo Alvarez has been promoted and will become the new President & GM of Almirall US, reporting directly to the CEO and serving on the Management Board effective immediately.

• The Board of Directors nominates Carlos Gallardo as Vice President of the Board

  11/9/2020

  Almirall, S.A. the global biopharmaceutical company based in Barcelona, has announced the nomination of Carlos Gallardo as Vice President of the Board of Directors effective immediately.

• Almirall demonstrates resilient performance year to date despite COVID-19 impacts

  11/9/2020

  Almirall, S.A. (ALM) the global biopharmaceutical company based in Barcelona, has announced its 9M 2020 financial results.

• WuXi Biologics and Almirall Sign Strategic Collaboration Agreement for Multiple Bispecific Antibodies Targeting Dermatology Diseases

  1/9/2020

  WuXi Biologics announced the signing of a strategic collaboration agreement enabling Almirall to leverage the proprietary WuXiBody™ platform to develop bispecific antibodies for dermatological diseases.

• Almirall Makes Shift to Specialty Medicine with Veeva CRM 

  11/5/2019

  Spain's leading pharmaceutical company drives seamless customer engagement across multiple stakeholders using face-to-face, email, and web

• 

  Almirall Exercises Licensing Option for Dermira's Atopic Dermatitis Drug

  6/25/2019

  The deal comes as Dermira plans to initiate Phase III studies in the U.S.

• Almirall Announces Late-Breaking Oral Presentation of KX2-391 Ointment in Two Phase III Studies at the American Academy of Dermatology Annual Meeting

  2/5/2019

  Results from Phase III pivotal studies to be featured at Late-Breaking Research Program on March 2, 2019

• Almirall Prodesfarma Key Drug Trials Disappoint Investors

  9/3/2008